Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. - Wikidata - wikimedia - TriplyDB

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

http://www.wikidata.org/entity/Q34431441

about

Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma Antitumor Responses of Invariant Natural Killer T Cells Adoptive T-cell therapy for cancer: The era of engineered T cells Adoptive T Cell Therapy Targeting CD1 and MR1 Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Challenges and opportunities of allogeneic donor-derived CAR T cells A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Chimeric antigen receptor-redirected T cells return to the bench Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.CD19 chimeric antigen receptor T cell therapy for haematological malignancies.New immunotherapeutic strategies for the treatment of neuroblastoma.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.Developing immunotherapeutic strategies to target brain tumors.Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Natural Killer T Cells in Cancer Immunotherapy Blood's 70th anniversary: CARs on the Blood highway.Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells.Immunotherapy for brain tumors: understanding early successes and limitations.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.

P2860

Q26771238-F4E013DF-99A1-455C-BF2E-08F73F3BDA8C Q26778648-71FB87A9-49D5-42E9-A1EC-D43DF4941C1E Q26800611-85D99B38-9659-43E6-B71F-93E0757F9D77 Q26998503-A8AC45C3-753F-4D3A-87BE-53F08493D03F Q33720359-2BA4A4D5-E245-4AD5-AA5A-8E15959DD66B Q35641721-B46160ED-6FCA-44B4-A989-ED7CE9CE3D88 Q36257036-9AAA148B-15D5-4A66-9DCB-C80A7B95EFE1 Q36413053-4BE56337-0BAE-4951-B338-EEB6BF2CD37B Q36951719-96C54EFE-ED80-4C70-B643-05F9EF203219 Q37058110-3E54D1DA-793D-4680-8540-F1211AF5BCAD Q37301510-FEB24C48-5D03-409C-A776-FD00081742DC Q37592957-0BE5180C-EFEB-4B74-80FC-71F9E6E7805B Q38370975-D92AC916-4E6E-4B66-9963-21FB7B94369C Q38389316-FA9B9CD6-CDB7-49CC-BCF4-11A87EE7F46E Q38666579-4FA1C798-E21E-4C2F-B1D7-C1043F195E82 Q38734173-2A88123C-B676-461F-A9F2-81CAA2CE2E18 Q38741113-8B195A39-3C83-4363-9811-0F51B99736BB Q38839878-9AE9299F-955A-4F40-9278-9BE8EF10F83D Q38851464-CEF7B867-E9BB-4D6B-AE1C-FAD5FC6BC0D5 Q38890717-77537A3F-B3B2-4528-9C3C-F3239339D4CD Q39057617-9DD25C0C-459B-436F-A822-4D93367E3962 Q41139823-1096225D-94B8-4F9B-8085-611DCEFCED2D Q42078314-8B7048A2-B7BA-46F5-A445-C697CB939A48 Q42428460-6E295E6B-B937-4DA5-844C-1E9B93EC950E Q43555934-213E351C-0668-451B-B324-9214B0D5A243 Q44851304-09CF2EC0-4E5B-41B9-AC59-715A33DB21CB Q45857417-F25AC096-C681-42BF-8FAC-06017A38BEA2 Q45868734-0BB08B4B-F4D0-4325-8AF5-AF18612CC5C8 Q45871070-64CB6E91-EDEB-460D-9DAA-06D7A84D67DD Q47094171-6294D314-7F36-41B3-B7E3-8AEA6EA6FAA1 Q47215994-632A9C92-FDCB-49A6-8126-870229180D93 Q47350839-A40FC445-1E4A-4B22-AB43-0A122D08062C Q47555498-5A62DD37-26EA-4B49-87DA-D886ED98072C Q47570404-2651AA55-4009-4D10-9C99-027149DBCDD4 Q48316500-B1D15833-365F-460F-B74B-C14F2EFB2136 Q49280922-BDEDBE90-613D-4622-9D06-F7443E5C46D1 Q50025651-958E3D00-F0C4-4B3F-AC86-38EAA6766015 Q50075685-9AB7B26D-F225-4B32-8A3A-45BA00D2BD20 Q52645931-1BE781D3-634D-4291-A625-2B6240C71A21 Q54967775-3FAFD807-C160-4F1D-A151-7F32A7D92B23

P2860

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

http://www.wikidata.org/entity/Q34431441

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@ast

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@en

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@nl

type

label

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@ast

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@en

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@nl

prefLabel

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@ast

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@en

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@nl

P1433

Q34431441-BC756404-6DC8-494F-B412-267EE0336F60

P1476

Q34431441-04654701-2EF9-4D90-A2D6-AF80E62ACDAC

P2093

Q34431441-221A00F3-BA0B-41D6-832C-CE6FA76E80F6

Q34431441-42BBEE78-8EBB-400C-88EA-696E3CC2E5DA

Q34431441-47931680-9C6B-4AEC-A4B8-E8025D74D210

Q34431441-71EF02D3-03FB-4BFD-BB85-1EA9960D758C

Q34431441-9E2061C8-8BBC-4544-9FDD-B4D33C0C1DC9

Q34431441-9FFC5609-B21D-4255-8C2A-4E30725703E2

Q34431441-A456BCF7-9640-4732-8D6D-75A9D9ECFEEA

Q34431441-B5311159-4170-4600-83A7-8F324D7B8618

Q34431441-B8A44B75-820A-4178-A096-DCA3EB37B42A

Q34431441-CCE57B13-06C4-4180-8036-E0EF28F7E4FA

P2860

Q34431441-0B418690-151F-43F8-8100-12D913EF56C3

Q34431441-0C96B60D-9820-487D-8053-694B5D38ECD4

Q34431441-0F392C7C-AA07-44E3-BC14-32DCC2C705AE

Q34431441-10B44116-3896-48D0-B108-8715BEAED37A

Q34431441-11A1BF05-47D1-4060-BD4F-3A349F33DAA1

Q34431441-1498EC66-10AA-434A-8A8D-8B2FD07316E9

Q34431441-154A5D55-D95E-4D3A-82C1-2F8EA7CAD5E1

Q34431441-1F487E03-6FC0-475B-8D17-E8A316708BFB

Q34431441-2031C904-0B82-4A95-935E-25481A143D78

Q34431441-261C3F20-3A43-47F7-9A1F-00184B13B6C8

P304

Q34431441-CB305634-AC53-4E86-95DC-8E39736BCC8E

P31

Q34431441-1E5439E0-0841-4F29-88A0-79343BD28ABF

P356

Q34431441-560972F8-953A-4917-95EB-C1AF138DC021

P407

Q34431441-CE6E384F-794A-4DA2-BF43-097B13C0B417

P433

Q34431441-B6B6EDA2-4646-4D05-A9FD-D7F35FFC2785

P478

Q34431441-29D10B47-1FE4-4B35-9C34-F3F9D6AFB231

P577

Q34431441-1C90A303-F664-4483-8ED6-D6AFB8612AC4

P5875

Q34431441-9F655955-F708-43A2-897B-56366D925481

P698

Q34431441-91D5FE4F-8998-488F-B421-B21B44DC2421

P921

Q34431441-56BABA26-0C83-4A5D-B86D-EBB8CDD033FD

P932

Q34431441-0CF245F0-4883-438F-8412-42388100A831

P356

BLOOD-2013-11-541235

P1433

P1476

Invariant NKT cells with chime ...... ffective cancer immunotherapy.

@en

P2093

Amy N Courtney

http://www.w3.org/2001/XMLSchema#string

Andras Heczey

http://www.w3.org/2001/XMLSchema#string

Daofeng Liu

http://www.w3.org/2001/XMLSchema#string

Ekaterina Marinova

http://www.w3.org/2001/XMLSchema#string

Eric Yvon

http://www.w3.org/2001/XMLSchema#string

Gengwen Tian

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Hao Liu

http://www.w3.org/2001/XMLSchema#string

Jie Wei

http://www.w3.org/2001/XMLSchema#string

John Hicks

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Differentiation of effector CD4 T cell populations (*)

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Model based period analysis of absolute and relative survival with R: data preparation, model fitting and derivation of survival estimates.

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

The basic principles of chimeric antigen receptor design.

P304

2824-2833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-11-541235

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264125948

http://www.w3.org/2001/XMLSchema#string

P698

25049283

http://www.w3.org/2001/XMLSchema#string

P921

P932

4215313

http://www.w3.org/2001/XMLSchema#string